Objectives: After the implementation of an active surveillance programme for MRSA in US Veterans Affairs (VA) Medical Centers, there was an increase in vancomycin use. We investigated whether positive MRSA admission surveillance tests were associated with MRSA-positive clinical admission cultures and whether the availability of surveillance tests influenced prescribers' ability to match initial anti-MRSA antibiotic use with anticipated MRSA results from clinical admission cultures.
Introduction
The unnecessary use of antibiotics active against MRSA threatens to increase resistance to these agents and exposes patients to the risk of adverse effects without compensatory health benefits. Even as the spectre of vancomycin-resistant Staphylococcus aureus looms, 1 empirical vancomycin use to cover MRSA has become widespread. Rapid diagnostics that help to accurately identify patients in need of anti-MRSA antibiotics are therefore of great interest.
In recent analyses, we observed a concerning trend of increasing vancomycin use 2 despite decreasing MRSA infections in the US Department of Veterans Affairs (VA) network of hospitals. This trend has been noted since October 2007 when VA launched a nationwide active surveillance programme to perform nasal tests for MRSA on all intensive care, medical and surgical wards. 3 Officially, the programme cautioned providers not to use the results to guide clinical therapy; 4 however, some experts suggested that these surveillance results could be used to curtail unnecessary vancomycin therapy. 5 -7 We speculated that the observed increase in vancomycin use in the VA system may have been an unintended consequence of the active surveillance efforts for MRSA. Increased awareness of MRSA may have increased the use of anti-MRSA antibiotics despite a reduction in MRSA infections, thus increasing unnecessary use of these agents. 8 We therefore explored the ability of admission MRSA nasal surveillance results to predict MRSA-positive admission cultures across the VA network. We originally hypothesized that instead of using MRSA surveillance tests to guide them, providers responded to a heightened awareness of MRSA by starting initial (hospital days 1 -2) anti-MRSA therapy more when admission surveillance tests were sent. In contrast, we hypothesized that admission culture results would be positively associated with consequent (hospital days 4+) anti-MRSA antibiotics.
Methods

Setting
This study was conducted using retrospective data from the VA healthcare system. VA is a comprehensive health system serving .8 million veterans in 152 medical centres throughout the USA and its territories. 9 Clinical microbiology and laboratory data were processed to identify MRSA surveillance tests and MRSA-positive clinical cultures. 10 Inpatient antibacterial use was measured using barcode medication administration (BCMA) data.
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Study period and population
All acute and intensive care admissions to medical or surgical wards between January 2005 and September 2010 were eligible for inclusion. Hospitals averaging ,10 inpatients per day on medical or surgical acute care wards were excluded. Hospitals with incomplete BCMA data were excluded to minimize inaccurate antibiotic prescription reports. 11 Admissions were included in our models if admission cultures were drawn and initial antibiotic therapy was administered.
Definitions
An admission surveillance test was defined as a nares swab for MRSA identification collected within the first two calendar days of admission. The laboratory methods used were not dictated by the study and ranged from culture to molecular methods. An admission culture was defined as any clinical culture except for stool cultures obtained within the same time period.
The use of systemic antibiotics was expressed as 'days of therapy' (DOT), defined as the administration of a specific antibiotic on a given day independent of the number, strength or route of individual doses. 12 An antibiotic was considered 'initial' therapy when a dose was administered during calendar days 1 or 2 of a hospitalization (admission day¼day 1), while doses given on or after day 4 were considered 'consequent', irrespective of the timing of microbiology result reporting. Day 3 was excluded because it represents a blend of initial and consequent therapy. We defined anti-MRSA antibiotics as intravenous vancomycin, intravenous daptomycin, linezolid (intravenous and oral) and intravenous quinupristin/dalfopristin. Tigecycline was not included in this analysis because of its additional broad Gram-negative spectrum. 13 An antibiotic course was defined to contain all doses of an antibiotic separated by no more than three calendar days. The principal International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis code was used to define the syndrome deemed to have precipitated the admission as previously reported.
14 A principal diagnosis of MRSA infection was defined as a principal diagnosis code of infection coupled with one of 041.12, 482.42, 038.12 or a V09 code.
Statistical methods
We analysed three models to investigate: (i) whether surveillance information could inform these decisions; (ii) whether MRSA surveillance information influenced providers' ability to anticipate MRSA-positive admission cultures with initial anti-MRSA antibiotics; and (iii) whether MRSA-positive admission cultures were associated with consequent anti-MRSA therapy. We used the diagnostic OR as a summary statistic of diagnostic test performance, which is the ratio of the odds of a positive test in disease relative to the odds of a positive test in the non-diseased. 15 Mixed-effects logistic regression was used to estimate the diagnostic OR in models predicting MRSA-positive admission cultures and consequent MRSA therapy. Random effects were modelled for facilities to account for clustering. Interaction terms for targeted variables and the presence of nasal MRSA surveillance results were included so that the influence of surveillance could be examined. All models used the subset of data from admissions with admission cultures and initial antibiotics administered as a marker of suspected community-onset infection. The model estimating the association between initial anti-MRSA antibiotics and MRSA surveillance results was restricted to admissions with surveillance tests. The model predicting consequent anti-MRSA antibiotic use was restricted to admissions with a length of stay of ≥4 days and where initial anti-MRSA antibiotics had been administered. Other potential covariates included as predictors in the regression model were calendar time, whether the patient was initially admitted to ICU versus non-ICU, personal remote or recent history of MRSA, classification of the principal diagnosis (ICD-9-CM) and whether a surveillance test was taken.
Sensitivity, specificity and predictive values were calculated on a peradmission basis to provide more clinically intuitive diagnostic test metrics. Descriptive statistics were used to describe anti-MRSA antibiotic use and admission culture data. t-tests were used for interval data and x 2 tests for dichotomous values.
All analyses were performed using STATA version 12.1 (2009; StataCorp, College Station, TX, USA) and a P value of ,0.05 was considered to be statistically significant in all cases.
Data source and Institutional Review Board approval
All data included in this study were obtained from the VA electronic medical record and were accessed through the Veterans Informatics and Computing Infrastructure. This research complied with all federal guidelines and VA policies relative to human subjects and clinical research. The study was retrospective and the Institutional Review Board waived the need for informed consent.
Results
Study population/number of admissions
Data from 129 of the 152 existing VA hospitals met inclusion criteria. Twenty-one hospitals were excluded because they had ,10 acute care beds listed and three additional hospitals were Jones et al.
excluded because complete data were not available. There were a total of 2.8 million acute care admissions during the study period across the 129 included hospitals, of which 569 815 met inclusion criteria for having admission cultures drawn and initial antibiotic therapy started.
Anti-MRSA antibiotic use, culture-taking practice and surveillance MRSA status was assessed on admission through surveillance testing in 54.4% of all included admissions during the study period. While few surveillance tests were performed early in the study period, numbers increased rapidly concomitant to the nationwide implementation of active MRSA surveillance in 2007 (Figure 1a ). General and MRSA status admission descriptors as well as the proportion of admissions receiving initial and consequent anti-MRSA antibiotics among admissions with and without surveillance testing are described in Table 1 .
Initial anti-MRSA antibiotics were administered during 189762 (33.3%) admissions in which admission cultures were obtained. For another 85 602 admissions, initial anti-MRSA antibiotics were given but no admission cultures were obtained. Of all anti-MRSA antibiotic starts, 81.9% were started within the first 2 days of included admissions. Vancomycin accounted for the majority of all anti-MRSA antibiotic DOT (overall 90.8%; facility median 92.9; IQR 90.1 -95.1). Overall yearly VA trends for initial anti-MRSA antibiotics increased (P, 0.001) and MRSA-positive admission cultures decreased (P,0.001) (Figure 1b) . MRSA surveillance to guide antibiotics?
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Diagnosis and initial therapy
We used the prescription of initial anti-MRSA antibiotics as a marker of providers' propensity to empirically treat for MRSA infections. Figure 2( Table 2 'Predictors of MRSA-positive admission cultures among admissions with surveillance tests'). To express the association between MRSA surveillance results and MRSA-positive admission cultures in terms familiar to clinical diagnosticians, we calculated sensitivities and specificities ranging from 58% -73% and 79% -87%, respectively, over different major diagnostic categories of principal diagnoses ( Table 3) . The sensitivity and specificity of surveillance over time ( Figure 2b ) were stable compared with that of initial anti-MRSA antibiotic therapy as shown in Figure 2 (a). The predictive values were similar across all clinical scenarios except for skin and soft tissue infections (Table 3) . Because there may be differences in predictive value between PCR and culture methods, we analysed a subset of 22 hospitals where times from admission to reported result were ,24 h for 90% of the time. Among 71 970 admissions, only specificity was significantly but substantially different from the overall category in Table 3 (85.2%; 95% CI 84.9% -85.4%).
To investigate the influence of surveillance results on providers' ability to anticipate admission culture results with appropriate initial anti-MRSA antibiotic therapy, we examined whether there was a difference in the diagnostic OR when surveillance results were absent compared with when they were present (Table 2 'Influence of surveillance results on prediction of MRSA-positive admission cultures'). Among all included admissions, the diagnostic ORs were not different without (OR 3.2; 95% CI 3.1-3.4) or with (OR 3.3; 95% CI 3.2-3.5) surveillance results.
Consequent therapy
Among admissions where admission cultures were obtained and initial anti-MRSA antibiotic therapy administered, there was a moderate association (OR 3.7; 95% CI 3. Jones et al.
antibiotics (Table 2 'Predictors of consequent anti-MRSA therapy among admissions meeting criteria and lasting ≥4 days'). Anti-MRSA therapy continued past hospitalization day 3 in 74.2% of cases; 72.8% continued when admission cultures were MRSA negative and 84.5% when MRSA positive (P, 0.001). The mean number of additional treatment days (past day 3) in these courses was 4.7 and 7.0 for MRSA-negative and -positive admissions, respectively (P, 0.001). As a measure of variance, a hospital one standard deviation above the mean proportion of MRSA-positive admission cultures would have an OR of 1.36. ID-NOS, infectious disease diagnosis, not otherwise specified. a Note that in each case there was a positive association between the outcome and admission to ICU among all admissions, but not in these particular subgroups.
MRSA surveillance to guide antibiotics?
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Discussion
In this large, retrospective multicentre study, we found no evidence that systematic MRSA nasal surveillance directly influenced the match between anti-MRSA antibiotic use and admission cultures, at least through 2010. This finding was somewhat surprising because nasal MRSA surveillance results were highly predictive of MRSA-positive admission cultures. The negative predictive value was high in most situations identified (.97%) except for skin and soft tissue infections (90.3%). The poorer performance in skin and soft tissue infections may be related to the limited sensitivity of nares testing for MRSA colonization, 16 particularly with community-acquired MRSA strains that are in large part responsible for these infections in the USA. 17, 18 Our analysis demonstrated that actual MRSA-positive admission culture rates decreased while the use of initial anti-MRSA antibiotics increased, i.e. that the decision to treat with anti-MRSA antibiotics on admission grew less specific over time. It was also apparent that consequent anti-MRSA antibiotic use was only moderately guided by admission culture results. The fact that anti-MRSA antibiotics continued past day 3 in 72.8% of admissions with MRSA-negative admission cultures suggests that these culture results are underutilized for clinical care.
Our findings of overall trends and the predictive value of MRSA surveillance tests are concordant with other studies. Decreases in MRSA infections have been reported widely. 19 -21 Another study of academic hospitals found widespread increases in vancomycin use. 22 Other studies have reported positively on the potential to use MRSA surveillance tests to guide antibiotic therapy.
-7
Limitations
Our models investigated the relationship between surveillance testing and anti-MRSA antibiotic prescription decisions during the same admission. It may still be possible that there was an indirect influence through changes in antibiotic-prescribing culture and increasing MRSA awareness. The measures of association that we reported are weighted averages of direct individual admission-level and indirect hospital-level effects. A more sophisticated analysis would be necessary to tease apart direct and indirect effects. 23 We used MRSA-positive admission culture as a surrogate for community-onset MRSA infection instead of reviewing each case; however, we were able to consistently apply definitions on a scale impractical for human manual annotation. We also focused mainly on MRSA, which is not the only indication for anti-MRSA therapy. Examples of other indications include coagulase-negative Staphylococcus, Enterococcus and b-lactam allergy. It could be that many more anti-MRSA treatment courses were justifiable than appeared to be the case in this analysis. A further limitation was that the MRSA initiative only comprised surveillance for nasal MRSA carriage with the shortcomings noted above.
Finally, since the initiative was implemented within VAMCs, which strictly follow standard treatment guidelines on a specific patient population (veterans), our results may not be entirely generalizable outside VA or the USA. However, the MRSA admission prevalence at VA Medical Centers is higher than that reported at many other facilities, 24 -29 which should increase the negative predictive value of MRSA surveillance results.
Practical implications
Our findings have significant clinical implications. Within VA, the Antimicrobial Stewardship Task Force 30 recently released a policy directing clinical pharmacists to review the medication profiles of patients treated with initial anti-MRSA therapy at low risk of MRSA infection after day 2 of therapy 5 -7 and to recommend de-escalation if specific criteria are met. Our findings provide evidence as to how MRSA surveillance for nasal carriage can rapidly help identify low-risk patients. This approach could reduce the amount of anti-MRSA therapy used and the inevitable adverse consequences of excessive use, as well as decrease costs.
Conclusions
The successful triage of patients at high risk of MRSA may enable selection of appropriate therapy at the right time such that four, sometimes competing, aims can all be concurrently achieved, namely prevention of the following: (i) morbidity and mortality; (ii) overuse of antibiotics; (iii) development of antibiotic resistance; and (iv) transmission of MRSA. Our findings suggest that it may be possible to use surveillance information for purposes other than what it was initially intended for, such as guiding antibiotic therapy decisions. Diagnostic technology has evolved to allow relatively rapid identification of MRSA. Given the reported median facility turnaround time of 12 h for nasal surveillance results, 31 future prospective trials could include therapy guided by surveillance results in conjunction with other risk criteria.
